BMRN vs RMBS · P/E 40, rev $1.76B vs P/E 34, rev $707.6M
Biomarin Pharmaceutical Inc (BMRN) versus Rambus Inc (RMBS) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Rambus Inc (RMBS) is a semiconductors company listed on US.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported RMBS revenue for 2025-12-31 was $707.6M. Net income was $230.5M. Revenue was up 27.1% from 2024-12-31 to 2025-12-31. RMBS currently screens at market cap $7.08B and trailing P/E 34.5.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. RMBS currently screens at market cap $7.08B and trailing P/E 34.5.
Not investment advice. Open the BMRN and RMBS stock pages for the full models.
Not investment advice.